Clinical trials: sponsored by ANRS, Emerging Infectious Diseases
HIV, Hepatitis Virus
Feasibility of Interventions on People Who Inject Drugs in Vietnam
This study aims at assessing the feasibility of implementing an interventional cohort of people who inject drugs in Haiphong, Viet Nam.
- Conditions
- HIV, Hepatitis Virus, Substance Abuse
- Trial name
- DRIVE-IN (NCT02573948)
- Testing
- no intervention is assessed
- Where
- Vietnam
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV I Infection
Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV Infection
Interleukin33 organize local immune reactions, especially at epithelial barriers. ST2 is the IL33 receptor. The sST2 rate is higher for patient living with HIV and is an independent predictable factor of mortality.
- Trial name
- NCT03622177
- Testing
- biopsie, blood drawn
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Substance-Related Disorders
Methylphenidate for Cocaine Dependence
This phase II pilot study aims at evaluating the benefits and the risks of methylphenidate (Concerta®) for the treatment of cocaine/crack dependence in terms of cocaine/crack use reduction and adverse events.
- Trial name
- ANRS STIMAGO (NCT03090269)
- Testing
- Methylphenidate Pill
- Where
- France
- Volunteers
- healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Cryptococcal Meningitis
Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS
The aim of the study is to evaluate systematic pre-antiretroviral cryptococcal antigen screening and pre-emptive fluconazole therapy in antigen positive patients, as a strategy to reduce morbidity and mortality due to AIDS…
- Trial name
- PreCASA (NCT02624453)
- Testing
- Fluconazole, Antiretroviral therapy
- Where
- Cameroon
- Volunteers
- 186 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?
This project aims at characterizing HIV-1 viral biofilms structural and functional properties and at deciphering its role as a new viral reservoir and as a new mode of viral spread.
- Trial name
- TRANSBioHIV (NCT01895920)
- Testing
- Blood sample
- Where
- France
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infected Patients With Cancer Treated by ICPi
ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)
A Multicenter, Observational, National Cohort for HIV Infected Patients with a Cancer treated by Immune-Checkpoint Inhibitors (ICPi) for less than one month or to be treated with an ICPi such as anti-PD-1 or anti-PDL-1 or…
- Trial name
- OncoVIHAC (NCT03354936)
- Testing
- Blood sample
- Where
- 56 sites in France
- Volunteers
- 50 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study
The primary objective is to measure the prevalence of according to the Frascati classification in a HIV-infected population aged between 55 and 70 years (exposed group) and to compare it with the prevalence of HIV-Associated…
- Trial name
- HAND55-70 (NCT02592174)
- Testing
- Health related quality of life and social and demographic informations, Neurocognitive assessment, cerebral images sub-study
- Where
- 6 sites in France
- Volunteers
- 220 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, HIV Infection
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
Primary Objective: To evaluate the efficacy (sustained virological response 12 weeks after end-of-treatment [SVR12]) of 12-week course of an interferon-free regimen combining sofosbuvir and weight-dosed ribavirin (genotype 2), or…
- Trial name
- TAC (NCT02405013)
- Testing
- Sofosbuvir, Ribavirin, Ledipasvir
- Where
- 4 sites in Cameroon, Côte d’Ivoire and 1 more
- Volunteers
- 120 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Cohort of HIV Associated Lymphomas
The incidence of lymphomas is increased among HIV infected patients. In 70 % of cases, those are Non Hodgkin's lymphomas (NHL) and Hodgkin lymphomas (HL) in 30% of cases.
- Trial name
- ANRS CO16 (NCT01164436)
- Where
- France
- Volunteers
- 205 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection, PREGNANCY
Evaluation of Raltegravir During the Third Trimester of Pregnancy
The purpose of this study is to assess the evolution of raltegravir concentration in the mother (between the 3rd trimester of pregnancy and one month post-delivery) and her neonate, when this drug is used to prevent…
- Trial name
- ANRS 160 RalFE (NCT02099474)
- Testing
- Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy
- Where
- France
- Volunteers
- 83 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
The principal objective is to evaluate the antiviral efficacy of 48 weeks treatment with the two-drugs combination dolutegravir(Tivicay®) and lamivudine(TEpivir®) in HIV-1 infected patients virologically suppressed with triple…
- Trial name
- NCT02527096
- Testing
- dolutegravir (Tivicay®) - Phase 1, lamivudine (Epivir®) - Phase 2, dolutegravir (Tivicay®) - Phase 2
- Where
- 18 sites in France
- Volunteers
- 110 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa
Multicenter, randomized, superiority trial to evaluate efficacy of a mono or bi-therapy of protease inhibitors with or without lamivudine over a period of 96 weeks. The primary outcome will be the failure rate at 96 weeks.
- Trial name
- MOBIDIP (NCT01905059)
- Testing
- monoPI - boosted lopinavir or boosted darunavir, bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
- Where
- 5 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 265 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C
The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian…
- Trial name
- ViZIR (NCT02099604)
- Testing
- Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
- Where
- Egypt
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis, HIV
Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into consideration the absence of data about R induction at this dose.
- Trial name
- RIFAVIRENZ (NCT01986543)
- Testing
- drug administration
- Where
- Uganda
- Volunteers
- 105 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Viral Hepatitis C, HIV
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
Aim of the study is to assess the efficacy and safety of 24 weeks of oral Sofosbuvir/Ledipasvir fixed-dose combination (FDC) in subjects with HCV genotype 1 infection and HIV co-infection, who have previously failed a NS3/4A…
- Trial name
- NCT02125500
- Testing
- Sofosbuvir/Ledipasvir fixed dose
- Where
- France
- Volunteers
- 68 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, HIV Seronegativity
Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
This cohort study should provide an exhaustive overview on long-term safety of various preventive HIV-vaccines administered in phase I and II clinical trials to healthy volunteers of the ANRS network.
- Trial name
- NCT00789789
- Where
- France
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, Chronic Hepatitis B
Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France
Populations from Sub-Saharan Africa represent one of the most dynamic immigration flows in France and are among the most exposed to HIV infection and hepatitis B.
- Trial name
- PARCOURS (NCT02566148)
- Volunteers
- 2,468 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men
This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada…
- Trial name
- IPERGAY (NCT01473472)
- Testing
- Truvada
- Where
- 7 sites in Canada, France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Cohort of Patients Naive of Antiretroviral Treatment at Enrollment
The purpose of this study is to evaluate the short, medium and long-term prognosis for newly diagnosed HIV patients.
- Trial name
- COPANA (NCT03137797)
- Where
- France
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Exposure to Hepatitis C Virus
Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C
This project is a prospective observational cohort study to quantify the risk of acquiring Hepatitis C virus (HCV) infection for patients and healthcare workers in Ain Shams University Teaching Hospital, Cairo, Egypt through: 1)…
- Trial name
- IMMHoTHep (NCT02826447)
- Where
- Egypt
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases